Literature DB >> 23775849

Downregulation of sulfotransferase expression and activity in diseased human livers.

Emine B Yalcin1, Vijay More, Karissa L Neira, Zhenqiang James Lu, Nathan J Cherrington, Angela L Slitt, Roberta S King.   

Abstract

Sulfotransferase (SULT) function has been well studied in healthy human subjects by quantifying mRNA and protein expression and determining enzyme activity with probe substrates. However, it is not well known if sulfotransferase activity changes in metabolic and liver disease, such as diabetes, steatosis, or cirrhosis. Sulfotransferases have significant roles in the regulation of hormones and excretion of xenobiotics. In the present study of normal subjects with nonfatty livers and patients with steatosis, diabetic cirrhosis, and alcoholic cirrhosis, we sought to determine SULT1A1, SULT2A1, SULT1E1, and SULT1A3 activity and mRNA and protein expression in human liver tissue. In general, sulfotransferase activity decreased significantly with severity of liver disease from steatosis to cirrhosis. Specifically, SULT1A1 and SULT1A3 activities were lower in disease states relative to nonfatty tissues. Alcoholic cirrhotic tissues further contained lower SULT1A1 and 1A3 activities than those affected by either of the two other disease states. SULT2A1, on the other hand, was only reduced in alcoholic cirrhotic tissues. SULT1E1 was reduced both in diabetic cirrhosis and in alcoholic cirrhosis tissues, relative to nonfatty liver tissues. In conclusion, the reduced levels of sulfotransferase expression and activity in diseased versus nondiseased liver tissue may alter the metabolism and disposition of xenobiotics and affect homeostasis of endobiotic sulfotransferase substrates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775849      PMCID: PMC3876809          DOI: 10.1124/dmd.113.050930

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  60 in total

Review 1.  Pathogenesis of alcoholic liver disease: newer mechanisms of injury.

Authors:  D W Crabb
Journal:  Keio J Med       Date:  1999-12

2.  Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver.

Authors:  Zhengbo Duanmu; Amy Weckle; Sevasti B Koukouritaki; Ronald N Hines; Josie L Falany; Charles N Falany; Thomas A Kocarek; Melissa Runge-Morris
Journal:  J Pharmacol Exp Ther       Date:  2005-12-09       Impact factor: 4.030

3.  Acetaminophen and phenol: substrates for both a thermostable and a thermolabile form of human platelet phenol sulfotransferase.

Authors:  C Reiter; R M Weinshilboum
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

Review 4.  Dopamine sulphate: an enigma resolved.

Authors:  G Eisenhofer; M W Coughtrie; D S Goldstein
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1999-04

5.  17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.

Authors:  T Narasaka; T Moriya; M Endoh; T Suzuki; S Shizawa; Y Mizokami; T Matsuoka; H Sasano
Journal:  Endocr J       Date:  2000-12       Impact factor: 2.349

6.  Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor.

Authors:  Hai-Lin Fang; Stephen C Strom; Hongbo Cai; Charles N Falany; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Mol Pharmacol       Date:  2005-01-05       Impact factor: 4.436

7.  Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response.

Authors:  Min Sun Kim; Judy Shigenaga; Art Moser; Carl Grunfeld; Kenneth R Feingold
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-06-15       Impact factor: 4.310

Review 8.  Redox-inflammatory synergy in the metabolic syndrome.

Authors:  Sean Bryan; Boran Baregzay; Drew Spicer; Pawan K Singal; Neelam Khaper
Journal:  Can J Physiol Pharmacol       Date:  2013-01-28       Impact factor: 2.273

9.  Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats.

Authors:  Y Finkel; A C Eklöf; L Granquist; P Soares-da-Silva; A M Bertorello
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

Review 10.  Structure and function of sulfotransferases.

Authors:  M Negishi; L G Pedersen; E Petrotchenko; S Shevtsov; A Gorokhov; Y Kakuta; L C Pedersen
Journal:  Arch Biochem Biophys       Date:  2001-06-15       Impact factor: 4.013

View more
  17 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 2.  Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment.

Authors:  Benjamin W Redan; Kimberly K Buhman; Janet A Novotny; Mario G Ferruzzi
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 3.  Design and Interpretation of Human Sulfotransferase 1A1 Assays.

Authors:  Ting Wang; Ian Cook; Thomas S Leyh
Journal:  Drug Metab Dispos       Date:  2015-12-09       Impact factor: 3.922

4.  Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.

Authors:  Michael J Doerksen; Robert S Jones; Michael W H Coughtrie; Abby C Collier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12-19       Impact factor: 2.441

Review 5.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2015-03-18       Impact factor: 3.922

7.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

9.  Bisphenol A sulfonation is impaired in metabolic and liver disease.

Authors:  Emine B Yalcin; Supriya R Kulkarni; Angela L Slitt; Roberta King
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-19       Impact factor: 4.219

10.  A microbial metabolite remodels the gut-liver axis following bariatric surgery.

Authors:  Snehal N Chaudhari; James N Luo; David A Harris; Hassan Aliakbarian; Lina Yao; Donggi Paik; Renuka Subramaniam; Arijit A Adhikari; Ashley H Vernon; Ayse Kiliç; Scott T Weiss; Jun R Huh; Eric G Sheu; A Sloan Devlin
Journal:  Cell Host Microbe       Date:  2021-01-11       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.